Safety Considerations in Emerging Biologic Treatments for Plaque Psoriasis
January 9th 2024Experts in dermatology emphasize the need to consider patients' overall well-being when evaluating the safety profiles of emerging biologic treatments for plaque psoriasis, taking into account the heightened levels of depression and anxiety in individuals with this condition.
Expert Insights into Emerging Biologic Psoriasis Treatments
January 9th 2024George Han, MD, discusses the latest biologic agents for plaque psoriasis, addressing the balance between efficacy and speed of response. Together with Dr. Leon Kircik, they emphasize the significance of comprehensive data for physician confidence and delve into the clinical utilization of these treatments, stressing the importance of baseline laboratory measurements for all prescribed patients.
Expert Insights into Emerging Topical Psoriasis Treatments
January 9th 2024Leon Kircik, MD, emphasizes the combined use of emerging topical treatments with systemic or biologic medications and the impact of the treatment vehicle on penetration. He also discusses the potential for longer use of steroidal options by reducing active product quantities through better penetrating vehicles and highlights the potential heightened efficacy of newer topical treatments and the gaps they may fill in the management of this condition.
Frontline Forum Part 4: A Greater Understanding of the Acne Vulgaris Armamentarium
August 23rd 2023In the final part of this Frontline Forum series, James Del Rosso, DO; Hilary Baldwin, MD; Neal Bhatia, MD; Christopher Bunick, MD, PhD; and Leon Kircik, MD, discuss the use of clascoterone cream 1%, differences in isotretinoin formulations, targeting sebum production, acne guidelines for patient care, and more.
Frontline Forum Part 3: A Greater Understanding of the Acne Vulgaris Armamentarium
August 21st 2023In part 3 of this Frontline Forum series, James Del Rosso, DO; Hilary Baldwin, MD; Neal Bhatia, MD; Christopher Bunick, MD, PhD; and Leon Kircik, MD, discuss the use of clascoterone cream 1%, differences in isotretinoin formulations, targeting sebum production, acne guidelines for patient care, and more.
Frontline Forum Part 2: A Greater Understanding of the Acne Vulgaris Armamentarium
August 16th 2023In part 2 of this Frontline Forum series, James Del Rosso, DO; Hilary Baldwin, MD; Neal Bhatia, MD; Christopher Bunick, MD, PhD; and Leon Kircik, MD, discuss the use of clascoterone cream 1%, differences in isotretinoin formulations, targeting sebum production, acne guidelines for patient care, and more.
Frontline Forum Part 1: A Greater Understanding of the Acne Vulgaris Armamentarium
August 14th 2023In part 1 of this Frontline Forum series, James Del Rosso, DO; Hilary Baldwin, MD; Neal Bhatia, MD; Christopher Bunick, MD, PhD; and Leon Kircik, MD, discuss the pathogenesis of acne vulgaris, the use of clascoterone cream 1%, differences in isotretinoin formulations, targeting sebum production, acne guidelines for patient care, and more.
Physician responds to Chester Valley concerns
December 1st 2006EDITOR'S NOTE: Dr. Leon Kircik is replying to a clarification from Chester Valley Pharmaceuticals that ran in our November issue on an article in the October issue, "Vehicles often drive treatment of difficult ailments." Atopiclair is Chester Valley Pharmaceutical's product. While Dr. Kircik was not the author of the article (he was interviewed by Senior Staff Correspondent John Jesitus) he did see the article before it went to press for his approval, as is Dermatology Times' standard practice with clinical articles.